Cognition Therapeutics Inc (CGTX) stock
Close on Nov 16, 2026Market cap $60.75MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $60.75M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.84
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$16.78M
- EPS, diluted
- -$0.19
- Book value per share
- $0.36
- Diluted shares
- 91M
Trading
- Next earnings
- Mar 25, 2027 (estimated, before the open)
- Previous close
- $0.68
- Open
- $0.69
- Day's range
- $0.61 – $0.69
- Volume
- 503,676
- Average volume (20 days)
- 416,964
- 52-week range
- $0.55 – $1.81
- RSI (14 days)
- 32.8
- Volatility (1 year)
- 95.8%
- Relative volume
- 0.93×
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | CGTX | S&P 500 | Difference | CGTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -12.5% | -3.1% | −9.4 pts | ||
| 3 months | -36.8% | -4.5% | −32.3 pts | ||
| Year to date | -52.7% | +9.4% | −62.0 pts | ||
| 1 year | -58.8% | +11.3% | −70.1 pts | ||
| 3 years | -36.1% | +70.4% | −106.5 pts | -13.9% | +19.4% |
| 5 years | -93.9% | +68.6% | −162.5 pts | -42.9% | +11.0% |
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cognition Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- News
- Results
- News
- Update
- News
About Cognition Therapeutics
Biological Products, (No Diagnostic Substances)
Cognition is a clinical-stage biopharmaceutical company that discovers and develops small molecule drug candidates for age-related degenerative disorders of the central nervous system and retina. The company focuses on developing disease-modifying therapies designed to protect neuronal synapses from toxic protein oligomers. Its primary pipeline candidate is zervimesine, also identified as CT1812, an orally administered therapeutic being evaluated for Alzheimer’s disease and dementia with Lewy bodies. Its target recipients are patients experiencing cognitive decline, mild cognitive impairment, and associated neurodegenerative conditions.
Company profile, executives and historyCognition Therapeutics stock: common questions
What is Cognition Therapeutics's stock price?
CGTX closed at $0.64 on Nov 16, 2026, down 6.03% on the day. Over the past 52 weeks it traded between $0.55 and $1.81.
What is Cognition Therapeutics's market cap?
Cognition Therapeutics was worth $60.75M at the close on Nov 16, 2026: the share price times the diluted shares outstanding.
What is CGTX's P/E ratio?
Cognition Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.19), so it has no meaningful P/E ratio.
Does Cognition Therapeutics pay a dividend?
No. Cognition Therapeutics has not paid a cash dividend over the last twelve months.
When does Cognition Therapeutics report earnings next?
Cognition Therapeutics is expected to report Q4 FY2026 results on Mar 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CGTX stock performed over the past year?
Including dividends, CGTX returned -58.8% over the past year, against +11.3% for the S&P 500.
How many CGTX shares are sold short?
7M shares were sold short at the latest FINRA report, 8.11% of the float, or 15.3 days of average trading volume.
Who are Cognition Therapeutics's competitors?
Companies most similar to Cognition Therapeutics by business, industry and size include ABOS, ALEC, NMRA, PASG, AVXL.
See a number that looks wrong?